Abstract
Emerging data suggest that liver mets are immune privileged and can induce systemic loss of tumour specific CD8+ T cells, leading to reduced anti-tumour immunity. Liver mets were shown to negatively predict the success of immunotherapy (as opposed to chemotherapy [chemo] or targeted therapy) in several cancer types. However, limited prospective data exist on the effect of immunotherapy in patients (pts) with liver mets.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
